Fintel · Oct 7, 2026
NASDAQ · EW
Edwards Lifesciences Corporation
Healthcare · Medical - Devices
$85.21
Up+$0.97 (+1.15%)
Updated Oct 10, 2026, 9:51 PM
SID Score
5.5/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 49.46B
- P/E ratio
- 36.1
- Dividend yield
- 0.00%
- 52-week range
- $74.66 – $96.29
- Volume
- 3.89M
- Avg. volume
- 4.51M
Price performance · EW
EW price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
EW closed at $85.21 after 21 trading sessions, up 1.00% for the selected period.
- Last close
- $85.21
- Period change
- +1.00%
- Period low
- $84.24
- Period high
- $89.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $84.60 | $85.34 | $83.22 | $85.21 | 3.89M |
| Oct 8, 2026 | $85.65 | $85.78 | $82.425 | $84.24 | 6.52M |
| Oct 7, 2026 | $86.65 | $87.30 | $85.49 | $85.78 | 3.51M |
| Oct 6, 2026 | $87.54 | $87.875 | $85.94 | $86.48 | 3.38M |
| Oct 5, 2026 | $85.635 | $87.57 | $85.34 | $87.23 | 3.32M |
| Oct 2, 2026 | $85.52 | $86.48 | $84.66 | $85.15 | 2.41M |
| Oct 1, 2026 | $85.99 | $86.8388 | $84.485 | $85.19 | 3.08M |
| Sep 30, 2026 | $87.16 | $87.49 | $85.72 | $86.32 | 4.89M |
| Sep 29, 2026 | $85.70 | $88.19 | $85.70 | $88.08 | 3.38M |
| Sep 28, 2026 | $86.00 | $87.33 | $85.56 | $86.83 | 3.23M |
| Sep 25, 2026 | $86.66 | $87.11 | $84.925 | $86.29 | 3.6M |
| Sep 24, 2026 | $86.54 | $87.12 | $85.63 | $85.73 | 3.87M |
| Sep 23, 2026 | $88.70 | $88.79 | $86.06 | $86.82 | 3.62M |
| Sep 22, 2026 | $89.00 | $89.66 | $88.495 | $88.78 | 3.53M |
| Sep 21, 2026 | $88.34 | $88.59 | $87.77 | $88.34 | 3.35M |
| Sep 18, 2026 | $88.03 | $88.77 | $87.47 | $88.26 | 4.26M |
| Sep 17, 2026 | $89.21 | $89.5788 | $88.00 | $88.25 | 3.88M |
| Sep 16, 2026 | $84.99 | $89.70 | $84.84 | $89.28 | 5.01M |
| Sep 15, 2026 | $85.03 | $86.025 | $84.47 | $85.74 | 3.78M |
| Sep 14, 2026 | $85.45 | $86.26 | $85.12 | $85.52 | 2.99M |
| Sep 11, 2026 | $87.51 | $87.755 | $83.81 | $84.37 | 3.8M |
Latest EW news
The latest Smart Investors Daily articles mentioning EW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EW research
Overview
Company profile and research snapshot.
Company profile
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $95.40
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 11, 2026 | BTIG | Buy | — |
| Jul 24, 2026 | Leerink Partners | Outperform | — |
| Jul 24, 2026 | Piper Sandler | Overweight | — |
| Jul 24, 2026 | JP Morgan | Overweight | — |
News briefing
Generated Oct 10, 2026, 9:24 PM
Why Is EW Up Today?
Edwards Lifesciences gained 1.15% today, rising $0.97 as Barclays initiated coverage of the medical device giant with an Overweight rating. This positive analyst endorsement reflects confidence in the company's growth prospects and market position in structural heart disease and critical care monitoring.
Bottom line: Today's modest gain reflects modest optimism from Barclays' Overweight initiation, signaling analyst confidence in EW's competitive positioning and growth catalysts. Investors should monitor competitive dynamics, regulatory developments, and quarterly procedure volume trends to assess whether this analyst support translates into sustained momentum.
Yahoo · Oct 7, 2026
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.
Yahoo · Oct 7, 2026
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
IRVINE, Calif., October 07, 2026--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
Benzinga · Oct 7, 2026
Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110
Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
